Geron Corporation (GERN) stock is experiencing a significant pre-market surge, jumping 9.17% following the release of its third-quarter earnings report and maintained buy ratings from analysts. This impressive pre-market rally builds upon the 5.50% gain seen during Wednesday's regular trading session, indicating strong investor confidence in the biotechnology company's future prospects.

The pre-market enthusiasm appears to be driven by a combination of factors, despite Geron reporting mixed financial results for Q3 2025. The company announced a quarterly adjusted loss of 3 cents per share, meeting analysts' expectations but showing a slight increase in losses compared to the same quarter last year. Revenue rose 67.1% to $47.23 million, falling short of the $52.88 million anticipated by Wall Street. However, investors seem to be focusing more on the company's strategic initiatives and market expansion plans rather than the revenue miss.

Adding fuel to the stock's upward momentum is the continued positive sentiment from Wall Street analysts. Multiple analysts have reaffirmed their buy ratings for Geron, with TD Cowen analyst Tara Bancroft maintaining a Buy rating and a price target of $4.00. Needham analyst Gil Blum also reiterated a Buy rating, citing the company's strong financial position despite a dip in Rytelo sales. The average consensus recommendation for Geron remains "buy," with Wall Street's median 12-month price target at $4.00, representing a potential 71.3% upside from its last closing price. This sustained analyst confidence, coupled with Geron's ongoing developments in treatments for hematologic malignancies, appears to be overshadowing the mixed quarterly results and driving the stock's impressive pre-market gain.